These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 28374645)

  • 1. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B; Cincotta AH
    Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study.
    Roe ED; Chamarthi B; Raskin P
    J Diabetes Res; 2015; 2015():834903. PubMed ID: 26060825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
    Chamarthi B; Ezrokhi M; Rutty D; Cincotta AH
    Postgrad Med; 2016 Nov; 128(8):761-769. PubMed ID: 27687032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus.
    Chamarthi B; Gaziano JM; Blonde L; Vinik A; Scranton RE; Ezrokhi M; Rutty D; Cincotta AH
    J Diabetes Res; 2015; 2015():157698. PubMed ID: 26060823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
    Vinik AI; Cincotta AH; Scranton RE; Bohannon N; Ezrokhi M; Gaziano JM
    Endocr Pract; 2012; 18(6):931-43. PubMed ID: 23186965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.
    Gaziano JM; Cincotta AH; Vinik A; Blonde L; Bohannon N; Scranton R
    J Am Heart Assoc; 2012 Oct; 1(5):e002279. PubMed ID: 23316290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quick-release bromocriptine for treatment of type 2 diabetes.
    Mikhail N
    Curr Drug Deliv; 2011 Sep; 8(5):511-6. PubMed ID: 21696353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Bromocriptine-QR as an Adjunctive Therapy on Glycemic Control in Subjects with Uncontrolled Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis.
    Yanto TA; Budiputri CL; Muljono MP; Chandra S
    J ASEAN Fed Endocr Soc; 2024; 39(1):95-105. PubMed ID: 38863918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus.
    Schwartz SS; Zangeneh F
    Postgrad Med; 2016 Nov; 128(8):828-838. PubMed ID: 27458683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.
    Scranton R; Cincotta A
    Expert Opin Pharmacother; 2010 Feb; 11(2):269-79. PubMed ID: 20030567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.
    Gaziano JM; Cincotta AH; O'Connor CM; Ezrokhi M; Rutty D; Ma ZJ; Scranton RE
    Diabetes Care; 2010 Jul; 33(7):1503-8. PubMed ID: 20332352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo.
    Scranton RE; Gaziano JM; Rutty D; Ezrokhi M; Cincotta A
    BMC Endocr Disord; 2007 Jun; 7():3. PubMed ID: 17592632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
    Ponssen HH; Elte JW; Lehert P; Schouten JP; Bets D
    Clin Ther; 2000 Jun; 22(6):709-18. PubMed ID: 10929918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromocriptine-QR therapy for the management of type 2 diabetes mellitus: developmental basis and therapeutic profile summary.
    Raskin P; Cincotta AH
    Expert Rev Endocrinol Metab; 2016 Mar; 11(2):113-148. PubMed ID: 30058874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
    Horton ES; Foley JE; Shen SG; Baron MA
    Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
    Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
    Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.